國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to anti-cancer therapeuti...

Elkabets, Moshe.

Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathwaysedited by Yosef Yarden, Moshe Elkabets.
其他作者:	Yarden, Yosef.
出版者:	Cham :Springer International Publishing :2018.
面頁冊數:	xx, 242 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Drug resistance in cancer cells.
電子資源:	http://dx.doi.org/10.1007/978-3-319-67932-7
ISBN:	9783319679327$q(electronic bk.)

Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways
Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways[electronic resource] /edited by Yosef Yarden, Moshe Elkabets. - Cham :Springer International Publishing :2018. - xx, 242 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.152196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

ISBN: 9783319679327$q(electronic bk.)

Standard No.: 10.1007/978-3-319-67932-7doiSubjects--Topical Terms:

281104
Drug resistance in cancer cells.

LC Class. No.: RC271.C5 / R475 2018

Dewey Class. No.: 616.994061

Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways
LDR:02199nmm a2200325 a 4500 001 533320
003 DE-He213
005 20180830165256.0
006 m d
007 cr nn 008maaau
008 181205s2018 gw s 0 eng d
020 $a 9783319679327$q(electronic bk.)
020 $a 9783319679303$q(paper)
024 7 $a 10.1007/978-3-319-67932-7 $2 doi
035 $a 978-3-319-67932-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5 $b R475 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b R433 2018
245 0 0 $a Resistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways $h [electronic resource] / $c edited by Yosef Yarden, Moshe Elkabets.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xx, 242 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.15
505 0 $a Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
520 $a This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
650 0 $a Drug resistance in cancer cells. $3 281104
650 0 $a Antineoplastic agents. $3 229375
650 0 $a Cancer $x Chemotherapy. $3 194707
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Cancer Research. $3 273660
700 1 $a Yarden, Yosef. $3 711677
700 1 $a Elkabets, Moshe. $3 808950
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 711051
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-67932-7
950 $a Biomedical and Life Sciences (Springer-11642)